🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07307066
Recruiting Not applicable

Real-Time Algorithm-Driven Ventilation Feedback to Improve Lung-Protective Ventilation in Patients With ARDS (REALVENT-study)

NCT07307066 · tracked via the Priya Life Science China tracker
Sponsor
Peking Union Medical College Hospital
Phase
Not applicable
Started
2025-12-30
Last updated
2026-07-01

Condition(s) studied

ARDS (Acute Respiratory Distress Syndrome)VILI (Ventilator-induced Lung Injury)Respiratory FailureCritical Illness

Investigational drug(s) / intervention(s)

REal-time Algorithm-driven Ventilation feedback to improve lung-protective ventilation in criticallyStandard ICU care

REal-time Algorithm-driven Ventilation feedback to improve lung-protective ventilation in critically: Patients in the intervention arm will receive real-time ventilator waveform monitoring through the respiratory dynamics monitoring and feedback RemoteVentilate ViewTM system. The system continuously collects high-frequency waveform data (flow, pressure, volume) directly from the ventilator interface and analyses the following metrics: Tidal volume (VT) indexed to predicted body weight, Driving pressure (ΔP), Plateau pressure (Pplat), and Mechanical power (MP). Patient-ventilator asynchrony (PVA) events will be also collected in the system, including double triggering, ineffective efforts, reverse triggering, and flow starvation, etc..

Standard ICU care: The control group will receive standard ICU care, including routine monitoring of ventilator parameters such as tidal volume, plateau pressure, and oxygenation status. No structured feedback or external ventilation reports will be provided. This reflects the prevailing standard of care in Chinese ICUs and is thus an appropriate comparator for assessing the added value of a real-time respiratory feedback platform.

Study summary

The REALVENT trial is designed to evaluate whether a real-time, algorithm-driven ventilation feedback strategy can improve lung-protective ventilation (LPV) achievement rates in critically ill patients receiving invasive mechanical ventilation. This multicentre randomised controlled trial will compare real-time respiratory waveform monitoring with automated feedback against standard ICU care. The primary endpoint is the LPV achievement rate over the first 72 hours.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 75 years * Receiving invasive mechanical ventilation via endotracheal intubation at the time of screening * Initiation of invasive mechanical ventilation within the past 24 hours * PaO₂/FiO₂ ≤ 200 mmHg on PEEP ≥ 8 cmH₂O or, if arterial blood gas is unavailable: SpO₂/FiO₂ ≤ 235 with SpO₂ ≤ 97% * Chest imaging (chest X-ray or CT) showing bilateral pulmonary infiltrates not fully explained by pleural effusions, lobar collapse, or pulmonary nodules * Respiratory failure not fully explained by cardiac failure or fluid overload * Expected to require invasive mechanical ventilation for ≥ 72 hours after enrollment Exclusion Criteria: * Receipt of extracorporeal membrane oxygenation (ECMO) or high-frequency oscillatory ventilation at screening * Brain death or anticipated withdrawal of life-sustaining treatment within 72 hours * Pregnancy * Known neuromuscular disease affecting spontaneous respiratory effort * Prisoners or individuals unable to provide informed consent or surrogate consent * Simultaneous enrollment in another interventional ICU study * Lack of digital infrastructure for real-time ventilator waveform acquisition

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Qujing Central Hospital of Yunnan Province Qujing Yunnan Recruiting

More Peking Union Medical College Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07307066 on ClinicalTrials.gov ↗ ← All trials in China